CHEMBIO DIAGNOSTICS, INC. (NASDAQ:CEMI) Files An 8-K Regulation FD DisclosureITEM 7.01.REGULATION FD DISCLOSURE.
On December 21, 2017, the Company issued a press release entitled "Chembio Diagnostics Announces Completion of U.S. Clinical Trial Evaluating DPP® HIV-Syphilis System". A copy of the press release is provided herewith as Exhibit99.1.
ITEM 9.01.FINANCIAL STATEMENTS AND EXHIBITS
Exhibits.
|
99.1 |
Press Release entitled "Chembio Diagnostics Announces Completion of U.S. Clinical Trial Evaluating DPP® HIV-Syphilis System" dated December 21, 2017. |
CHEMBIO DIAGNOSTICS, INC. ExhibitEX-99.1 2 ex99_1.htm EXHIBIT 99.1 FOR PRESS RELEASE Chembio Diagnostics Announces Completion of U.S. Clinical Trial Evaluating DPP® HIV-Syphilis System U.S. Regulatory Submission for DPP® HIV-Syphilis System Expected in Q1 2018 MEDFORD,…To view the full exhibit click here
About CHEMBIO DIAGNOSTICS, INC. (NASDAQ:CEMI)
Chembio Diagnostics, Inc. (Chembio), and its subsidiary, Chembio Diagnostic Systems, Inc., develop, manufacture, market and license rapid point-of-care diagnostic tests (POCTs) that detect infectious diseases. The Company’s products available are rapid tests for the detection of human immunodeficiency virus (HIV) 1/2 antibodies, and a multiplex rapid test for the detection of HIV and Syphilis antibodies. The HIV 1/2 rapid tests employ in-licensed and lateral flow technologies that are used with all blood matrices as samples, and are manufactured in a standard cassette format, a dipstick format and a barrel format. Its HIV 1/2 rapid antibody detection test incorporates the Dual Path Platform (DPP) POCT technology. The DPP HIV 1/2 Assay detects antibodies to HIV 1 and 2 in oral fluid samples, as well as in all blood matrices. The Company’s product pipeline includes a multiplex rapid test for earlier detection of HIV and a multiplex test that detects HIV and Syphilis specific antibodies.
